Associated tags: Liver disease, Therapy, Liver, NASH, THR, Medication, Fatty liver disease, Patient, Pharmaceutical industry, Madrigal
Locations: RARE, AST, BONE, WEST CONSHOHOCKEN, PA, US
Retrieved on:
Wednesday, January 3, 2024
CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 pm PT.
Key Points:
- CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 pm PT.
- The presentation will be webcast and an archived recording will be available for replay in the Investors section of the Madrigal website after the event.
Retrieved on:
Friday, December 22, 2023
The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Points:
- The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- The equity awards were granted as inducement material to the employees’ acceptance of employment with the company.
- The employees received, in the aggregate, 10,571 time-based restricted stock units.
- The restricted stock units vest ratably over four years, subject to each such employee’s continued employment as of the vesting date.
Retrieved on:
Monday, November 27, 2023
The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Points:
- The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- The equity awards were granted as inducement material to Ms. Huntsman’s and the other employees’ acceptance of employment with the company.
- Ms. Huntsman received options to purchase 10,077 shares of Madrigal’s common stock, and 7,834 time-based restricted stock units.
- All such restricted stock units vest in a 25% increment on each of the first through fourth anniversaries of the grant date.
Retrieved on:
Tuesday, November 21, 2023
Digital,
Commercial,
NASH,
Fatty liver disease,
Robotics,
Schering-Plough,
Information system,
Thomas Jefferson University,
Quality,
COVID-19,
Teva Pharmaceuticals,
Growth,
Patient,
Head,
Therapy,
Automation,
Information technology CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer.
Key Points:
- CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer.
- Bill Sibold, Chief Executive Officer of Madrigal, stated, “Ron’s skillset and depth of digital experience will be a tremendous asset for Madrigal as we prepare for a first-to-market launch of resmetirom.
- Mr. Filippo began his career in the biopharmaceutical industry at Schering-Plough, supporting information technology operations in R&D and Quality.
- Mr. Filippo stated, “I look forward to working with the Madrigal team to enhance the company’s information technology and AI capabilities during a pivotal period of growth and transformation.
Retrieved on:
Wednesday, November 15, 2023
The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Points:
- The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- The equity awards were granted as an inducement material to the employees’ acceptance of employment with the company.
- All awards described under (1) and (2) above shall be subject to each such employee’s continued employment as of the vesting date.
- The exercise price per share for the stock options described above is $146.00.
Retrieved on:
Friday, November 10, 2023
THR,
Hepatology,
MRE,
AASLD,
CAP,
Hepatitis,
Therapy,
Incremental cost-effectiveness ratio,
ELF,
Fibrosis,
Priority review,
Treatment,
Cirrhosis,
Lipid,
Division,
Non-alcoholic fatty liver disease,
Fatty liver disease,
Atherosclerosis,
Abstract,
Diabetes,
Histology,
Biopsy,
NDA,
Electronic health record,
ALT,
Artificial intelligence,
University,
Marie Cassidy,
NASH,
Intelligence,
Research,
Disease,
LDL,
FDA,
Radiation Exposure Compensation Act,
Medical imaging,
Pharmaceutical industry,
Boston,
Patient,
Risk,
Gastroenterology Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.
Key Points:
- Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.
- It is the only investigational therapy for NASH that has achieved both fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial.
- Resmetirom also reduced levels of LDL cholesterol and other lipids that are associated with heart disease.
- Resmetirom is an investigational therapy and has not been approved by the FDA or any other regulatory authority.
Retrieved on:
Friday, November 10, 2023
Senior,
The Carroll School,
Serono,
Patient,
Immunology,
Neurology,
Oncology,
Therapy,
Carroll School of Management,
Fatty liver disease,
Multiple sclerosis,
Merck Serono,
NASH,
Pharmaceutical industry,
Nursing,
Madrigal,
Dupilumab,
Sanofi,
Boston College,
History CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer.
Key Points:
- CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer.
- This included executing the launch of Dupixent, a first-in-class therapy which has grown into an industry-leading medicine.
- In 2022, Ms. Huntsman’s business unit was responsible for over $10 billion in annual net sales.
- Bill Sibold, Chief Executive Officer of Madrigal, stated, “Carole Huntsman’s leadership skills and experience are a perfect fit for Madrigal as we prepare for a first-to-market launch of resmetirom in the U.S. She has an extensive track record of specialty launch success and excels in building and leading high-performing teams that deliver innovative new therapies to patients with serious diseases.
Coordinated Specialty Care,
FDA,
Non-alcoholic fatty liver disease,
Research,
Nine Months,
Biomarker,
Therapy,
Cirrhosis,
Agency,
Treatment,
Histology,
Priority review,
Disease,
Hepatology,
NASH,
Fibrosis,
Employee compensation in the United States,
Incremental cost-effectiveness ratio,
New Drug Application,
Intelligence,
Diabetes,
NAFLD,
Atherosclerosis,
Fatty liver disease,
Electronic health record,
Pharmaceutical industry,
Cryptocurrency,
Medical imaging,
Rare-earth element,
Risk,
Patient,
Sanofi,
Nature Medicine,
Dupilumab,
Madrigal At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.
Key Points:
- At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.
- The Agency noted that it is not currently planning to hold an advisory committee meeting to discuss the application.
- In October 2023, we completed a public offering and received an additional $472.0 million in net cash proceeds.
- These increases in interest income were due primarily to higher average interest rates in 2023.
Retrieved on:
Thursday, November 2, 2023
CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at three upcoming investor conferences:
Key Points:
- CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at three upcoming investor conferences:
5:00 pm ET on Wednesday, November 8, 2023.
- 3:00 pm ET on Wednesday, Nov 29, 2023.
- 1:00 pm ET on Thursday, November 30, 2023.
- The fireside chats will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.
Retrieved on:
Thursday, October 12, 2023
CONSHOHOCKEN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees with a grant date of October 10, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan.
Key Points:
- CONSHOHOCKEN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees with a grant date of October 10, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company's 2023 Inducement Plan.
- The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- The equity awards were granted as inducement material to the employees’ acceptance of employment with the company.
- The employees received, in the aggregate, 11,139 time-based restricted stock units, which vest ratably over four years, subject to each such employee’s continued employment as of the vesting date.
